Ligand Pharmaceuticals Incorporated Stock Analysis & AI Score
Ligand Pharmaceuticals Incorporated (LGND) has an ST Score of 61.9 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $339.43 price target (+13.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Ligand Pharmaceuticals Incorporated (LGND) has an ST Score of 61.9 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $339.43 price target (+13.5% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- MomentumA
- GrowthA-
- Financial StrengthB
- ForecastC+
- ValuationF
- Piotroski5/9
Contact
LGND stock: frequently asked questions
What is LGND's ST Score?
Ligand Pharmaceuticals Incorporated (LGND) has an ST Score of 61.9 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LGND a buy, hold, or sell?
Analysts rate LGND a Buy, with a price target of $339.43 (+13.5% vs the current price). Our ST Score grades it B (61.9/100). The ST Score is a data-driven signal, not a recommendation.
What are LGND's factor grades?
Valuation F, Profitability A+, Financial Strength B, Momentum A, Growth A-, Forecast C+.
What is LGND's valuation grade?
Ligand Pharmaceuticals Incorporated (LGND) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LGND's growth grade?
Ligand Pharmaceuticals Incorporated (LGND) earns a growth grade of A-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LGND's profitability grade?
Ligand Pharmaceuticals Incorporated (LGND) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LGND's financial strength grade?
Ligand Pharmaceuticals Incorporated (LGND) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LGND?
The average analyst price target for Ligand Pharmaceuticals Incorporated (LGND) is $339.43 from 18 analysts, which is +13.5% versus the recent price of $299.04.
What is LGND's Piotroski score?
Ligand Pharmaceuticals Incorporated (LGND) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.